Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2;135(1):70–78. doi: 10.1097/CM9.0000000000001785

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Examples of using the nomogram to predict the individual survival probability by manually placing straight lines across the diagram. A 32-year-old man was found positive HIV-antibodies for 7 months and with the treatment of HAART. (A) A large circular, heterogeneous mass with necrosis was found inside the left cervical area II (white arrow). (B) Two irregular, heterogeneous lesions were found in the liver (black arrow). DLBCL was confirmed by biopsy. The patient received a chemotherapy regimen of CHOP and OS time was 14 months. The total points are 227 points. This patient is predicted to have a 58% probability of surviving for 1 year, 40% probability of surviving for 2 years, and 31% probability of surviving for 3 years (black line). CHOP: Cyclophosphamide, doxorubicin, vincristine and prednisolone; DLBCL: Diffuse large B-cell lymphoma; HAART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; OS: Overall survival.